Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078266 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10074297 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10078268 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10078265 | 0.84 | TGM2 (0.46) | TGM2CA1CA2PREPDPP4 | |
| SCHEMBL10054478 | 0.84 | TGM2 (0.46) | TGM2CA1CA2PREPDPP4 | |
| SCHEMBL10054472 | 0.84 | DPP4 (0.44) | TGM2PREPDPP4DPP7DPP8 | |
| SCHEMBL10078074 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10077082 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10074996 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTGM2CA1CA2 | |
| SCHEMBL10075286 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRTGM2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | ALDH1A1 961/4885TSHR 3716/4885TGM2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.